Cancer – AALL1731: A Study to Investigate Blinatumomab in Combination with Chemotherapy in Patients with Newly Diagnosed B-Lymphoblastic Leukemia

What is the goal of this study?

The overall goal of Part I of this study is to collect information about leukemia and patient response to the first phase of treatment, called Induction. The rest of therapy is called post-Induction (Part II). The goal of post-Induction therapy is to get rid of any remaining leukemia cells and keep the leukemia from coming back. Researchers also want to understand if children with localized B-LLy receiving “standard risk” B-ALL therapy maintain good treatment outcomes.

Who can join the study?

This study may be a good fit for children and young adults who:

• Are B-ALL patients without DS, between 1 and 9 years old
• Are B-ALL patients with DS, between 1 and 30 years old
• Are B-LLy patients with or without DS, between 1 and 30 years old
• Are B-ALL patients without DS with an initial white blood cell count of greater than 50,000/μL
• B-ALL patients with DS are eligible regardless of the presenting WBC
• Individuals with newly diagnosed B-cell ALL, with or without Down syndrome:
  • Greater than 25% blasts on a BM aspirate;
    • OR if a BM aspirate is not obtained or is not diagnostic of B-ALL, the diagnosis can be established by a pathologic diagnosis of B-ALL on a BM biopsy;
    • OR a complete blood count (CBC) documenting the presence of at least 1,000/μL circulating leukemic cells;
  • OR individual has newly diagnosed B-cell LLy Murphy Stages I or II (see Appendix VII for staging), with or without Down syndrome.

What will happen if my child takes part in this study?

You can read more about this study on clinicaltrials.gov.

Who can I contact for more information?

To learn more, call 206-987-2106 or email the study coordinator.